Pilot trial of intravenous (IV) infusion of a replication selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 in treatment of refractory cancer patients

被引：0
|
作者：
Nemunaitis, J
Cunningham, C
Tong, A
Edelman, G
Paulson, S
Mitch, D
Post, L
Freeman, S
机构：
[1] US Oncol, Dallas, TX USA
[2] Onyx Corp, Richmond, CA USA
来源：
CANCER GENE THERAPY | 2003年 / 10卷
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
33
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 21 条
  • [1] Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
    Nemunaitis, J
    Cunningham, C
    Tong, AW
    Post, L
    Netto, G
    Paulson, AS
    Rich, D
    Blackburn, A
    Sands, B
    Gibson, B
    Randlev, B
    Freeman, S
    CANCER GENE THERAPY, 2003, 10 (05) : 341 - 352
  • [2] Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
    J Nemunaitis
    C Cunningham
    A W Tong
    L Post
    G Netto
    A S Paulson
    D Rich
    A Blackburn
    B Sands
    B Gibson
    B Randlev
    S Freeman
    Cancer Gene Therapy, 2003, 10 : 341 - 352
  • [3] Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
    J Nemunaitis
    C Cunningham
    A Buchanan
    A Blackburn
    G Edelman
    P Maples
    G Netto
    A Tong
    B Randlev
    S Olson
    D Kirn
    Gene Therapy, 2001, 8 : 746 - 759
  • [4] Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
    Nemunaitis, J
    Cunningham, C
    Buchanan, A
    Blackburn, A
    Edelman, G
    Maples, P
    Netto, G
    Tong, A
    Randlev, B
    Olson, S
    Kirn, D
    GENE THERAPY, 2001, 8 (10) : 746 - 759
  • [5] Phase I dose escalation trial of intravenous infusion of ONYX-015 in patients with refractory cancer
    Nemunaitis, J
    Cunningham, C
    Edelman, G
    Berman, B
    Kirn, D
    CANCER GENE THERAPY, 1999, 6 (06) : S16 - S17
  • [6] Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
    Nemunaitis, J
    Khuri, F
    Ganly, I
    Arseneau, J
    Posner, M
    Vokes, E
    Kuhn, J
    McCarty, T
    Landers, S
    Blackburn, A
    Romel, L
    Randlev, B
    Kaye, S
    Kirn, D
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 289 - 298
  • [7] Phase I dose escalation trial of intravenous (IV) infusion of CI-1042 (ONYX-015) in patients with refractory cancer
    Nemunaitis, J
    Cunningham, C
    Uprichard, M
    Kim, D
    CANCER GENE THERAPY, 2000, 7 (12) : S8 - S8
  • [8] Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
    D Kirn
    Gene Therapy, 2001, 8 : 89 - 98
  • [9] Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
    Kirn, D
    GENE THERAPY, 2001, 8 (02) : 89 - 98
  • [10] A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer
    Kaye, S
    Nemunaitis, J
    Ganly, I
    Posner, M
    Vokes, E
    Kuhn, J
    Heise, C
    Maack, C
    Kirn, D
    ANNALS OF ONCOLOGY, 1998, 9 : 22 - 22
123